Printer Friendly

SANDOZ PHARMACEUTICALS NAMES TIM ROTHWELL PRESIDENT AND CEO

 SANDOZ PHARMACEUTICALS NAMES TIM ROTHWELL PRESIDENT AND CEO
 EAST HANOVER, N.J., June 23 /PRNewswire/ -- Sandoz Pharmaceuticals Corporation announced today that Tim Rothwell has been named president and chief executive officer.
 Daniel Wagniere, chairman of the board, said that as president and chief executive officer, Rothwell will be responsible for the everyday operations of the company's prescription and over-the-counter marketing and sales divisions, research and development, and manufacturing operations. Wagniere said Rothwell will assume his duties in early July.
 In making the announcement, Wagniere noted that Rothwell had a successful career with Sandoz Pharmaceuticals for 17 years where his last position was chief operating officer, pharmaceuticals operations. Recently, Rothwell has held senior level positions with Bristol-Myers Squibb Co. and Burroughs Wellcome Co.
 "Tim Rothwell is re-joining Sandoz Pharmaceuticals' at a time when the company is pursuing an extensive program of expansion and cooperative ventures in the United States. He is eminently qualified to lead this effort and we welcome him back among us," said Wagniere.
 Based in East Hanover, N.J., Sandoz Pharmaceuticals Corporation is the largest of six business divisions that comprise Sandoz Corporation, the U.S.-based subsidiary of Sandoz Limited of Basel, Switzerland.
 -0- 6/23/92
 /CONTACT: David L. Winter, 201-503-8600, or William O'Donnell, 201-503-7070, both of Sandoz Pharmaceuticals/ CO: Sandoz Pharmaceuticals Corporation ST: New Jersey IN: MTC SU: PER


PS-OS -- NY051 -- 2866 06/23/92 12:53 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 23, 1992
Words:233
Previous Article:DR. CALVERT H. SMITH ANNOUNCES RESIGNATION; PLANS TO RE-ENTER PUBLIC EDUCATION IN CINCINNATI
Next Article:KNIGHT-RIDDER ANNOUNCES DIVIDEND
Topics:


Related Articles
REJEANGE NAMED TO HEAD STERLING WINTHROP PHARMACEUTICALS GROUP
BURROUGHS WELLCOME CO. APPOINTS NEW VICE PRESIDENT, MARKETING AND SALES
SANDOZ NAMES RONALD SCHMID EXECUTIVE DIRECTOR, EXTERNAL AFFAIRS
CORANGE LIMITED APPOINTS DR. MAX LINK AS CHIEF EXECUTIVE OFFICER
PHARMACEUTICAL EXECUTIVE MAX LINK ELECTED DIRECTOR OF PROTEIN DESIGN LABS
JACQUES F. REJEANGE NAMED PRESIDENT AND CHIEF OPERATING OFFICER OF STERLING WINTHROP INC.; APPOINTMENT SIGNALS COMPANY POISED FOR GROWTH
JACQUES F. REJEANGE NAMED CHIEF EXECUTIVE OFFICER OF STERLING WINTHROP INC. SUCCEEDING LOUIS P. MATTIS
MANAGEMENT CHANGE AT SANDOZ PHARMACEUTICALS CORPORATION, EAST HANOVER, N.J.
MARK A. PULIDO NAMED CHIEF OPERATING OFFICER
CELGENE ELECTS NEW BOARD MEMBER

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters